Meridian Bioscience (VIVO) Earns News Sentiment Score of 0.05
News coverage about Meridian Bioscience (NASDAQ:VIVO) has trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Meridian Bioscience earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.1054137676113 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Meridian Bioscience (NASDAQ VIVO) traded down $0.20 during midday trading on Friday, hitting $14.25. 322,941 shares of the company traded hands, compared to its average volume of 293,953. The company has a current ratio of 5.82, a quick ratio of 4.04 and a debt-to-equity ratio of 0.28. Meridian Bioscience has a 12 month low of $12.45 and a 12 month high of $16.45. The stock has a market capitalization of $602.89, a P/E ratio of 27.94 and a beta of 0.98.
Meridian Bioscience (NASDAQ:VIVO) last issued its earnings results on Thursday, January 25th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $52.30 million for the quarter, compared to the consensus estimate of $49.00 million. Meridian Bioscience had a net margin of 10.46% and a return on equity of 17.00%. The firm’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.15 earnings per share. equities analysts predict that Meridian Bioscience will post 0.69 EPS for the current year.
Several research analysts have commented on VIVO shares. Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Friday, November 17th. Canaccord Genuity lifted their target price on shares of Meridian Bioscience from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Friday, January 26th. Finally, BidaskClub downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.